BloggingStocks

Bristol-Myers Squibb is in an uptrend

Joseph Lazzaro — Thu, 03 Dec 2009 17:15:00 EST

Filed under: Bristol-Myers Squibb (BMY), Stocks to Buy

Biopharmaceutical company Bristol-Myers Squibb (BMY) is performing on schedule, which is why I'm reiterating my buy rating for the company's shares, first recommended on June 1, 2009 at a price of $20.11. If you bought BMY in June, you're up about 24%.

Look for a 6-8% revenue increase for BMY in 2010, boosted by revenue gains in key proprietary drugs, led by Plavix (for the prevention of stroke, heart attack, and vascular disease). Also look for impressive results from new products Orencia (for rheumatoid arthritis) and Sprycel (for leukemia); BMY's nutritional products also should register a good year. The First Call FY2009/FY2010 EPS estimates for BMY are $2.02 to $2.21.

Continue reading Bristol-Myers Squibb is in an uptrend

Bristol-Myers Squibb is in an uptrend originally appeared on BloggingStocks on Thu, 03 Dec 2009 17:15:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments

Cramer on BloggingStocks: Sanofi has lots of upside catalysts

Jim Cramer — Mon, 23 Nov 2009 10:00:00 EST

Filed under: Analyst Reports, Pfizer (PFE), Market Matters, Bristol-Myers Squibb (BMY), Merck and Co (MRK), Lilly (Eli) (LLY), Deere and Co (DE), Stocks to Buy, Potash Corp. of Saskatchewan (POT)

From TheStreet.com Network

TheStreet.com's Jim Cramer says it looks like the patent worries aren't so dire after all.

Now that we see that health care reform is not going to bring price caps or socialization of medicine, we are beginning to see some real expansion in the drug stocks, including Merck (MRK) (Cramer's Take), Bristol-Myers (BMY) (Cramer's Take) and Lilly (LLY) (Cramer's Take). But there is one drug stock that is continually met with skepticism -- Sanofi Aventis (SNY) (Cramer's Take), the French vaccine and pharmaceutical maker run by Christian Viehbacher. The resistance is obvious, as his biggest two drugs are coming off patent very soon, and his hope is that by 2013 the company might again reach 2008 levels.

Sounds like there's no reason to buy this one. Sounds like its 4% dividend isn't safe.

Continue reading Cramer on BloggingStocks: Sanofi has lots of upside catalysts

Cramer on BloggingStocks: Sanofi has lots of upside catalysts originally appeared on BloggingStocks on Mon, 23 Nov 2009 10:00:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments

It's still a good time to buy BMY

Joseph Lazzaro — Wed, 23 Sep 2009 17:00:00 EST

Filed under: Bristol-Myers Squibb (BMY), Stocks to Buy

I'm reiterating my Buy rating for Bristol-Myers Squibb (NYSE: BMY), first recommended on June 1, 2009 at a price of $20.11.

The low, single-digit revenue growth story remains intact for Bristol-Myers Squibb in FY2009. Hence, place BMY in the category of a get-ahead-of-the-pack play.

Continue reading It's still a good time to buy BMY

It's still a good time to buy BMY originally appeared on BloggingStocks on Wed, 23 Sep 2009 17:00:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments

Good news for a new AstraZeneca drug

Mark Fightmaster — Mon, 31 Aug 2009 10:30:00 EST

Filed under: Good news, Industry

There is good news surfacing for pharmaceutical firm AstraZeneca (NYSE: AZN) this morning. Turns out a new drug produced by AZN helps reduce heart patients' chances of dying by more than 20% when compared to the standard treatment. The drug is designed to prevent blood clots in heart patients.

The study followed 18,624 patients from 2006 to 2008, with roughly half taking rival medicine Plavix and the other half taking AZN's Brilinta. The results show that patients taking Brilinta had a 4.5% chance of dying, compared to a 5.9% chance for patients on Plavix.

Continue reading Good news for a new AstraZeneca drug

Good news for a new AstraZeneca drug originally appeared on BloggingStocks on Mon, 31 Aug 2009 10:30:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments

Time to scoop up some shares of Bristol-Myers Squibb

Joseph Lazzaro — Mon, 01 Jun 2009 18:20:00 EST

Filed under: Bristol-Myers Squibb (BMY), Stocks to Buy

Readers of this space know that the investment bias is toward large-cap companies with demonstrated business models and who have a competitive advantage in established markets, preferably with a favorable, global trend as a support. And with that in mind, Bristol-Myers Squibb (NYSE: BMY) is worth a review.

In general, analysts forecast low, single-digit revenue growth for BMY in FY2009, weighed-down primarily by unfavorable foreign currency trends.

Continue reading Time to scoop up some shares of Bristol-Myers Squibb

Time to scoop up some shares of Bristol-Myers Squibb originally appeared on BloggingStocks on Mon, 01 Jun 2009 18:20:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments

Earnings highlights: P&G, DreamWorks, E*Trade, Netflix, Under Armour, Humana and more

Trey Thoelcke — Sat, 02 May 2009 14:40:00 EST

Filed under: Earnings Reports, Time Warner (TWX), Pfizer (PFE), Motorola (MOT), Exxon Mobil (XOM), Viacom (VIA), Revlon (REV), Netflix, Inc. (NFLX), Bristol-Myers Squibb (BMY), Domino's Pizza (DPZ), Procter and Gamble (PG), U.S. Steel (X), Under Armour'A' (UA), E*TRADE (ETFC)

Here are some highlights from this past week's earnings coverage from BloggingStocks:

Bristol-Myers Squibb Co. (NYSE: BMY) Q1 profit fell despite strong sales of Plavix and Abilify.
Check Point Software Technologies Inc. (NASDAQ: CHKP) was downgraded based on its guidance.
Domino's Pizza Inc. (NYSE: DPZ) strong Q1 results were boosted by early debt retirement.
DreamWorks Animation SKG Inc. (NYSE: DWA) strong Q1 results were driven by Madagascar 2.
Endo Pharmaceuticals Holdings Inc. (NASDAQ: ENDP) Q1 results led to an analyst's downgrade.
E*Trade Financial Corp. (NASDAQ: ETFC) widened its Q1 loss, sending shares sharply lower.

Continue reading Earnings highlights: P&G, DreamWorks, E*Trade, Netflix, Under Armour, Humana and more

Earnings highlights: P&G, DreamWorks, E*Trade, Netflix, Under Armour, Humana and more originally appeared on BloggingStocks on Sat, 02 May 2009 14:40:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments

Bristol-Myers' first-quarter earnings fall

Mark Fightmaster — Tue, 28 Apr 2009 10:10:00 EST

Filed under: Earnings Reports, Bristol-Myers Squibb (BMY)

Pharmaceutical firm Bristol-Myers Squibb (NYSE: BMY) announced that strong sales of Plavix and Abilify (an anti-clotting and psychiatric drug, respectively) helped boost the company's quarterly revenue. The boost wasn't enough though, as higher taxes and a litigation charge weighed on the company's profit, pulling it 3.5% lower.

BMY's quarterly earnings totaled 32 cents per share, a penny worse than a year ago. However, earnings excluding items would have been 48 cents per share (simple math tells me that the charges were 16 cents per share). These charges included a litigation charge that helped settle a shareholder lawsuit. Quarterly revenue checked in at $5.02 billion, which was 3% higher than the first quarter of 2007. Excluding the effects of the strong dollar, BMY's sales would have increased 8%. Expectations called for higher sales of $5.13 billion, but lower per-share earnings of 47 cents per share.

Continue reading Bristol-Myers' first-quarter earnings fall

Bristol-Myers' first-quarter earnings fall originally appeared on BloggingStocks on Tue, 28 Apr 2009 10:10:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments

Sanofi-Aventis (SNY) plunges on Plavix threat in Europe

Eliza Popescu — Fri, 09 May 2008 13:12:00 EST

Filed under: Bad News, Products and Services, Launches, Consumer Experience, Competitive Strategy, Bristol-Myers Squibb (BMY)

Shares of French drug maker Sanofi-Aventis (NYSE: SNY) have been tumbling more than 5% in morning trading on news that a Swiss drug maker said it expects to receive approval to sell a generic version of Sanofi's anti-clotting agent Plavix.

History is repeating itself. After facing generic competition in the United States to its second-biggest product in 2006, Sanofi-Aventis is now dealing with a similar threat in Europe. Competition concerns came after Switzerland's Schweizerhall Holding AG announced it would launch a copy of the Plavix blood thinner that could be bought for a lower price. Schweizerhall said it expects German regulators to approve its generic version of Plavix, called clopidogrel.

Sanofi-Aventis's fears about generic competition are justified as the company had to fight against a similar situation less than a year ago. Back in 2006, Bristol-Myers Squibb Co. (NYSE: BMY), which develops the product with Sanofi, saw a big plunge in its sales after Canadian generics company Apotex Inc. launched a cut-price copy of the drug.

Continue reading Sanofi-Aventis (SNY) plunges on Plavix threat in Europe

Sanofi-Aventis (SNY) plunges on Plavix threat in Europe originally appeared on BloggingStocks on Fri, 09 May 2008 13:12:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments

Eli Lilly challenges Bristol-Myers with blood thinner

Douglas McIntyre — Mon, 05 Nov 2007 08:58:00 EST

Filed under: Products and Services, Bristol-Myers Squibb (BMY), Lilly (Eli) (LLY)

Bristol-Myers Squibb (NYSE: BMY)'s blood thinner Plavix is the second-largest selling drug in the world. It brought in over $3.4 billion in sales during the first nine months of this year. Eli Lilly (NYSE: LLY), however, believes it has a better treatment [subscription required]. According to The Wall Street Journal, its "new drug, known as prasugrel, is intended to treat patients on the verge of a heart attack." The new treatment can stop the build-up of platelets in the blood within thirty minutes

Lilly has a number of drugs going "off patent" in the next seven years. If these are not replaced, 50% of the company's revenue is at risk. It is not clear how long it will take the FDA to approve the drug, if it ever will.

The Journal writes that "in the head-to-head study, 9.9% of patients on prasugrel suffered either a heart attack, stroke or death from a cardiovascular cause, compared with 12.1% of those given Plavix. That is a 19% reduction in risk favoring prasugrel."

With new drugs, though, there is always a catch. Prasugrel is 32% more likely than Plavix to cause major bleeding.

Now the politics of drug approval will kick in. Experts for Bristol-Myers will say the new treatment is too dangerous and that Plavix is as close to perfect as a blood thinner can be. Lilly will claim that it can adjust the dose to cut down on bleeding and will get a legion of doctors to attest to that.

In the end, the patient can bleed to death or have a heart attack. Does it matter how he died?

Douglas A. McIntyre is an editor at 247wallst.com.

Eli Lilly challenges Bristol-Myers with blood thinner originally appeared on BloggingStocks on Mon, 05 Nov 2007 08:58:00 EST. Please see our terms for use of feeds.

Read | Permalink | Email this | Comments

Earnings highlights: Apple (AAPL), Merrill Lynch (MER), UAL (UAUA), and many others

Trey Thoelcke — Sat, 27 Oct 2007 11:40:00 EST

Filed under: Earnings Reports, Microsoft (MSFT), Apple Inc (AAPL), Amazon.com (AMZN), Motorola (MOT), Estee Lauder (EL), Halliburton (HAL), Netflix, Inc. (NFLX), New York Times'A' (NYT), Aetna Inc (AET), American Express (AXP), Anheuser-Busch InBev (BUD), Avery Dennison Corp (AVY), Boeing Co (BA), Bristol-Myers Squibb (BMY), Merrill Lynch (MER), Coach Inc (COH), Comcast Cl'A' (CMCSA), Countrywide Financial (CFC), United Parcel'B' (UPS), Merck and Co (MRK), Lockheed Martin (LMT), Hasbro Inc (HAS), Amgen Inc (AMGN), UAL Corp (UAUA), Dow Chemical (DOW), Texas Instruments (TXN), EMC Corp (EMC), Juniper Networks (JNPR), JetBlue Airways (JBLU), General Dynamics Corp (GD)

The earnings crunch continues to roll along, and here are a some highlights of this past week's earnings coverage from BloggingStocks:

Aetna Inc. (NYSE: AET) beat expectations and raised its full-year guidance.
Amazon.com Inc. (NASDAQ: AMZN) beat estimates by a penny and offered a poor outlook.
American Express Co. (NYSE: AXP) delivered a positive surprise, with profits up 10%.
Amgen Inc. (NASDAQ: AMGN) beat estimates, but revenue was flat.
Anheuser-Busch Cos. (NYSE: BUD) beat expectations on strength of international sales and partner brands.
Apple Inc. (NASDAQ: AAPL) blew past expectations. See our conference call live blog.
Avery Dennison Corp.'s (NYSE: AVY) net sales up, EPS down, both due to the Paxar acquisition.
Baidu.com Inc. (NASDAQ: BIDU) beat expectations, but wariness about its growth potential lingers.
Boeing Co. (NYSE: BA) beat expectations but lowered its guidance.
Bristol-Myers Squibb (NYSE: BMY) beat expectations on the strength of Plavix sales.
CNH Global's (NYSE: CNH) profit nearly doubled, beating estimates by 15%.
Coach Inc. (NYSE: COH) beat estimates by a penny, but offered a conservative outlook for the holidays.
Comcast Corp. (NASDAQ: CMCSA) met EPS expectations but cut its cash flow forecast.
Countrywide Financial Corp. (NYSE: CFC) reported a $1.2 billion loss, but predicts a profit in the next quarter.

Continue reading Earnings highlights: Apple (AAPL), Merrill Lynch (MER), UAL (UAUA), and many others

Earnings highlights: Apple (AAPL), Merrill Lynch (MER), UAL (UAUA), and many others originally appeared on BloggingStocks on Sat, 27 Oct 2007 11:40:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments

Bristol-Myers Squibb (BMY) rides Plavix sales to higher earnings

Beth Gaston Moon — Thu, 25 Oct 2007 12:44:00 EST

Filed under: Earnings Reports, Products and Services, Bristol-Myers Squibb (BMY)

Bristol-Myers Squibb (NYSE: BMY) announced today that third-quarter earnings were solidly higher, resulting in an increased target for overall 2007 earnings. In the latest reporting period, the drug manufacturer posted net income of $858 million, or 43 cents per share, up from a year-ago profit of $338 million (17 cents per share). Excluding items, the company banked 38 cents per share, or a penny better than Wall Street's expectations.

Revenue was higher during the period as well, up 22% to $5.05 billion, edging out analysts' consensus view of $5.02 billion.

Helping the company achieve these robust profits was BMY's blood-thinning medication Plavix, which saw sales double to $1.25 billion. The company is continuing a legal battle with Apotex over a generic version of Plavix, which hit shelves last August but has been pulled amid a patent dispute. The Plavix patent is scheduled to expire in 2011. Generic competition had negative repercussions for cholesterol drug Pravachol, which saw sales drop 55% in the third quarter as a result.

Continue reading Bristol-Myers Squibb (BMY) rides Plavix sales to higher earnings

Bristol-Myers Squibb (BMY) rides Plavix sales to higher earnings originally appeared on BloggingStocks on Thu, 25 Oct 2007 12:44:00 EST. Please see our terms for use of feeds.

Read | Permalink | Email this | Comments

Bristol-Myers CEO fired - effective immediately!

Melly Alazraki — Tue, 12 Sep 2006 10:57:00 EST

Filed under: Management, Law, Magazines

If The Wall Street Journal posted a breaking news story yesterday ahead of the official announcement, as Sarah Gilbert pointed out late last night, then it must have been true. And so it is. Bristol-Myers Squibb's board of directors has fired its chief executive officer Peter Dolan, effective immediately.

Not only has Dolan failed in his attempt to hold off cut-rate generics for Plavix, Bristol-Myers' top seller drug (among his other missteps over the years), but according to new information, a federal monitor also urged the company to fire the CEO and the General Counsel, Richard Willard (also to be dismissed).

With Apotex launching its generic Plavix earlier than expected, shareholders have intensified their pressure for a management change as Plavix contributes about 30% to Bristol's profits. But the calls to oust Dolan could be heard even before as analysts and investors found his performance lacking -- especially with the accounting scandal to inflate revenue that happened under his watch and the overpaying on drug deals. All left investors unhappy.

James Cornelius, formerly head of medical device maker Guidant Corp., was named by the board as the interim CEO. Cornelius is also a former chief financial officer for Eli Lilly.

Once the rumors of the possible management change started, Bristol-Myers shares have gained more than 1.5% after losing ground for quite some time during Dolan's years as CEO. Yesterday, Prudential even upgraded Bristol-Myers shares from underweight to overweight ahead of today's announcement. Analysts clearly believe the management change could win back investors' confidence.

Bristol-Myers CEO fired - effective immediately! originally appeared on BloggingStocks on Tue, 12 Sep 2006 10:57:00 EST. Please see our terms for use of feeds.

Read | Permalink | Email this | Comments

Bristol-Meyers gears for Plavix rival

Michael Canfield — Tue, 08 Aug 2006 14:45:00 EST

Filed under: SEC Filings, Good news, Bad News, Industry, Competitive Strategy

Bristol-Myers Squibb (BMY) is expecting a competitor to produce a generic version of their popular drug Plavix, and is putting out the word it will vigorously defend its patent rights in the United States and abroad, they said in their quarterly filing with the SEC.

Shares fell $1.56, or 6.9%, to $21.21 in premarket activity after the comments were made. This follows a rough couple weeks for BMY as shares have dropped over 12% since the launching of a investigation in alleged anti-trust activity around this same drug. [The shares have remained at about $20.20 most of the day.]

Plavix is a blood thinner. The needs of public who can benefit from less expensive drugs, and of the companies that seek profits and funds for expensive and speculative R&D, is just about the thorniest issue in capitalism that I can think of. Sooner or later, every drug that proves useful gets knocked off.

Michael Canfield doesn't own stock in Bristol-Myers.

Bristol-Meyers gears for Plavix rival originally appeared on BloggingStocks on Tue, 08 Aug 2006 14:45:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments